Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by Jesus4Prezon Nov 27, 2020 11:15pm
1017 Views
Post# 31993699

Jane King Interview

Jane King InterviewI listened again to the brief interview done during the Spring lockdown period.  It is interesting that at that time Don mentioned (around 6 min 30 sec) that 'we will be co-developing from this stage forward with a major pharmaceutical company'.   https://www.youtube.com/watch?v=0v54hV7Jeec

Given the plan has been in place already for over six months to co-develop, it can't be too long now until something gets announced.  Hopefully Don can go into this Christmas season feeling like a hero in the eyes of all his shareholders.  

If Don has been involved in a multi-billion dollar negotiation, with multiple parties, under multiple different formats, then I give him respect for walking the fine line of providing hope to his shareholders without breaching any confidentiality agreements.  His option one in the Chinese Investor Presentation, and his comments back in the spring about co-developing can be seen as stringing investors along, or they can be viewed as offering hope to weary shareholders, without saying too much.  I anticipate we will have a major partner soon.  If so, on that day I will send Don an email covneying my respect and appreciation for sharing the little bits that he could.  

From day one, I have been impressed with the insider ownership in this company and the complete lack of selling by any insiders.  Their shares will appreicate on the same day as mine.  Hopefully soon.

J4P


<< Previous
Bullboard Posts
Next >>